within Pharmacolibrary.Drugs.ATC.M;

model M01AE14
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.8,
    Cl             = 0.0008833333333333333,
    adminDuration  = 600,
    adminMass      = 0.2,
    adminCount     = 1,
    Vd             = 0.00014000000000000001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.022000000000000002,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Dexibuprofen is the S(+)-enantiomer of ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID) used for the treatment of pain, inflammation, and fever in conditions such as rheumatoid arthritis and osteoarthritis. It is approved and used in Europe and other countries, but not in the United States.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated in healthy adult volunteers after single oral dose administration.</p><h4>References</h4><ol><li><p>Balakrishnan, P, et al., &amp; Choi, HG (2009). Enhanced oral bioavailability of dexibuprofen by a novel solid self-emulsifying drug delivery system (SEDDS). <i>European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V</i> 72(3) 539–545. DOI:<a href=&quot;https://doi.org/10.1016/j.ejpb.2009.03.001&quot;>10.1016/j.ejpb.2009.03.001</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/19298857/&quot;>https://pubmed.ncbi.nlm.nih.gov/19298857</a></p></li><li><p>Kim, SR, et al., &amp; Kim, CK (2011). Dry elixir formulations of dexibuprofen for controlled release and enhanced oral bioavailability. <i>International journal of pharmaceutics</i> 404(1-2) 301–307. DOI:<a href=&quot;https://doi.org/10.1016/j.ijpharm.2010.11.020&quot;>10.1016/j.ijpharm.2010.11.020</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/21093566/&quot;>https://pubmed.ncbi.nlm.nih.gov/21093566</a></p></li><li><p>Gliszczyńska, A, &amp; Sánchez-López, E (2021). Dexibuprofen Therapeutic Advances: Prodrugs and Nanotechnological Formulations. <i>Pharmaceutics</i> 13(3) –. DOI:<a href=&quot;https://doi.org/10.3390/pharmaceutics13030414&quot;>10.3390/pharmaceutics13030414</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33808908/&quot;>https://pubmed.ncbi.nlm.nih.gov/33808908</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end M01AE14;
